A Phase 2 Study Of Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory Neuroblastoma

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT07527169
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Metastatic Olfactory Neuroblastoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Zanzalintinib — DRUG
    Given orally

Study Details

The goal of this clinical research study is to learn if zanzalintinib can help to control recurrent/metastatic ONB. The safety of zanzalintinib will also be studied.

Key Dates

Start date
Oct 1, 2026
Status verified
Apr 2026
Primary completion
Jul 1, 2028
Completion
Jul 1, 2030

Study Design

Enrollment
16 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Phase 2: Treatment with Zanzalintinib
    Participants will be enrolled into a single cohort (N=16). Enrolled participants will receive Zanzalintinib at a dose of 60 mg orally once daily in a 28-day cycle.

Primary Outcome Measure

Safety and Adverse Events (AEs) [ Time Frame: Through study completion; an average of 1 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
UT MD AndersonHoustonTexas77030
Luana Sousa, MD
[email protected]
713-628-5674
Luana Sousa, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Houston, TX

By research site
UT MD Anderson· Houston, TX

Related Studies